US, Australia, and Bengaluru-based Bugworks, a clinical-stage multi-indication therapeutics startup,announced that it has raised $18 million in Series B1 funding. The round was led by Lightrock India and included existing investors
Bugworks is a clinical-stage biopharmaceutical company founded in February 2014 with the goal of developing novel anti-infectives and immuno-oncology (IO) therapeutic assets using cutting-edge science from the fields of computational biology, pharmacology, structural biology, and medicinal chemistry.
Commenting on the latest funding Anand Anandkumar, CEO, Bugworks Research, said, “We are very excited about our lead clinical asset BWC0977 that is potentially the first novel truly broad-spectrum antibacterial drug in nearly five decades. We are very honored to welcome a syndicate of world class investors, who join our committed existing-investors in supporting our dual mission of combating AMR and hard to treat cancers.”